ClinConnect ClinConnect Logo

Main Menu

Search for Trials
Browse by Condition
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT04026451

Spectral Edge Frequency From Spectral EEG Analysis to Guide Deep Sedation in the Critical Care Setting (Pilot)

Launched by UNIVERSITY OF CHILE · Jul 18, 2019

Download PDF Apply for Trial

Trial Information

Current as of August 27, 2025

Withdrawn

Keywords

Sedation Eeg Mechanical Ventilation Critical Care Propofol

ClinConnect Summary

To determine whether deep sedoanalgesia guided by the spectral edge frequency 95 decreases propofol consumption with respect to deep sedoanalgesia guided by the sedation-agitation scale in patients hospitalized in the Intensive Care Unit under mechanical ventilation.

* Group intervention: sedation will be guided by SEF95 and SAS. Patients will be sedated to keep a SAS 1-2 with a SEF95 between 10 to 13 Hz.
* Group control: sedation will be guided by SAS. However, SEF95 will be also recorded but covered.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Older than 18 years
  • • Indication of deep sedation with propofol and fentanyl for more than 48 h
  • Exclusion Criteria:
  • • Brain damage
  • • Cognitive impairment
  • • Allergy to propofol or fentanyl
  • • Limitation of therapeutic effort
  • • Liver chronic disease Child C
  • • Prone positioning and use of neuromuscular blocking agents

About University Of Chile

The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.

Locations

Santiago, Rm, Chile

Santiago, Rm, Chile

Patients applied

0 patients applied

Trial Officials

Antonello Penna, MD/PhD

Principal Investigator

University of Chile

Rodrigo Gutiérrez, MD

Principal Investigator

University of Chile

Felipe Maldonado, MD

Principal Investigator

University of Chile

José Ignacio Egaña, MD/PhD

Principal Investigator

University of Chile

Eduardo Tobar, MD

Principal Investigator

University of Chile

Verónica Rojas, Nurse/MSc

Principal Investigator

University of Chile

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials